潰瘍性結腸炎

Ulcerative Colitis

2 種介入成分有評級——按證據強度從高到低排序

🔬 實證評級速查
🟠 C 薄弱證據益生菌 × 潰瘍性結腸炎

白話說:證據還很薄弱,不足以當成有效的療法。

證據分數 61 分(滿分 100)  · 發布狀態:可參考,但附帶但書

🇹🇼 台灣有獨立規範💊 留意藥物交互作用
這樣判讀,是參考了這些單位:
  • US FDA 態度:持保留
    展開原文引用
    「FDA has not approved any probiotic product for use as a drug or biological product in infants of any age」
  • EU EFSA 態度:不支持
    展開原文引用
    「a cause and effect relationship had not been established between the consumption of a combination of bacterial strains and reduction of gastro-intestinal discomfort」
  • UK NHS 態度:持保留
    展開原文引用
    「There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them.」

評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v10。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 📊 證據資料庫原始頁面

🔬 實證評級速查
🟡 B 初步證據比菲德氏菌 BB536 × 潰瘍性結腸炎

白話說:有初步證據,但研究規模還小,別當成定論。

證據分數 59 分(滿分 100)  · 發布狀態:可參考,但附帶但書

🇹🇼 台灣有獨立規範
這樣判讀,是參考了這些單位:
  • 第三方營養資料庫(國際)
    展開原文引用
    「Probiotics (Also known as: probiotic) are microorganisms that can have a positive effect on health. Examine catalogs evidence at the umbrella 'Probiotics' level rather than for individual strains such」
  • US FDA 態度:支持
    展開原文引用
    「GRN No. 877 — Bifidobacterium longum BB536. Intended use: ingredient in term infant formula at a level of 1 x 10^8 CFU per gram of product. FDA closure date: December 26, 2019. FDA letter: 'FDA has no questions' regarding the safety of Bifidobacterium longum BB536 when used as described in the notice. (Earlier GRN 268 covered use in conventional foods/beverages.)」
  • EU EFSA 態度:持保留
    展開原文引用
    「Scientific Opinion on the substantiation of health claims related to Bifidobacterium longum BB536 and improvement of bowel regularity (ID 3004), normal resistance to cedar pollen allergens (ID 3006), and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 3005) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Conclusion: Bifidobacterium longum BB536 does not improve…」

評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v7。本評級僅供衛教參考,不取代醫師診斷與處方。 · 📊 證據資料庫原始頁面